Aficamten, an experimental drug developed by Cytokinetics, significantly improved exercise capacity in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), according to results from the Phase 3 SEQUOIA-HCM clinical trial. Published in the New England Journal of Medicine, the data indicates that once-daily oral dosing safely reduced obstruction in the heart’s left ventricle, offering a potential new therapeutic pathway for managing this genetic condition.
Clinical Trial Results and Patient Outcomes
The SEQUOIA-HCM trial enrolled 282 participants with symptomatic oHCM who were already receiving standard-of-care treatments, such as beta-blockers or calcium channel blockers. Researchers randomized patients to receive either aficamten or a placebo over a 24-week period.
According to the study findings, patients treated with aficamten demonstrated a statistically significant improvement in peak oxygen consumption—a primary measure of exercise capacity—compared to the placebo group. The trial met its primary endpoint, showing that the drug effectively lowered the left ventricular outflow tract (LVOT) gradient, which is the hallmark of the obstruction in oHCM. Reducing this gradient helps the heart pump blood more efficiently and alleviates symptoms such as shortness of breath and chest pain.
Mechanism of Action in Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy is a condition where the heart muscle cells enlarge and the walls of the heart chambers thicken, often causing the heart to work harder to pump blood. In the obstructive form of the disease, this thickened muscle blocks or reduces blood flow from the left ventricle to the rest of the body.
Aficamten acts as a cardiac myosin inhibitor. By binding to cardiac myosin—the motor protein responsible for muscle contraction—the drug reduces the number of active cross-bridges that generate force. This mechanism decreases the hyper-contractility characteristic of oHCM, effectively relaxing the heart muscle and reducing the obstruction at the outflow tract. This targeted approach differs from traditional treatments like beta-blockers, which work by slowing the heart rate rather than addressing the underlying contractile defect.
Safety Profile and Regulatory Status
Throughout the 24-week trial, aficamten was generally well-tolerated by participants. The study reported that the incidence of adverse events was similar between the treatment and placebo arms. A critical concern with myosin inhibitors is the potential for excessive reduction in left ventricular ejection fraction (LVEF), which can lead to heart failure. Investigators monitored LVEF closely; the trial data indicated that significant drops in ejection fraction were infrequent and typically reversible upon dose adjustment or discontinuation.
Cytokinetics has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of aficamten in the treatment of symptomatic oHCM. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date for late 2024, at which point the agency will decide on the drug’s approval for clinical use.
Comparison with Existing Therapies
The current landscape for treating oHCM includes surgical options like septal myectomy—a procedure to remove part of the thickened heart muscle—and alcohol septal ablation. For patients who are not candidates for surgery or who continue to experience symptoms despite standard medication, mavacamten, another cardiac myosin inhibitor, was previously approved by the FDA in 2022.
The introduction of aficamten represents a competitive shift in the market. While both drugs belong to the same pharmacological class, clinicians will be looking at long-term safety data and the titration requirements of each agent to determine the best fit for individual patient profiles. Future clinical trials are expected to provide more data on the long-term impact of these therapies on structural heart changes and overall patient survival.
Related reading